Orexigen Therapeutics, Inc. (OREX) Posts Q4 Loss of 9c/Share

Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q4 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $857 thousand versus the consensus estimate of $940 thousand.

For earnings history and earnings-related data on Orexigen Therapeutics, Inc. (OREX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
• SBC Medical Group Holdings Incorporated (SBC) Misses Q2 EPS by 2c
• JD.com (JD) Tops Q1 EPS by 66c